Cargando…

Development and validation of the Myasthenia Gravis TeleScore (MGTS)

OBJECTIVE: The aim of our study was to validate the Myasthenia Gravis TeleScore (MGTS), a scale for the evaluation of MG patients in telemedicine. INTRODUCTION: COVID-19 pandemic has boosted telemedicine in clinical practice. It could be crucial in the care of neurological patients with chronic dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pasqualin, F., Guidoni, S. V., Albertini, E., Ermani, M., Frangiamore, R., Vanoli, F., Antozzi, C., Mantegazza, R., Bonifati, D. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883006/ https://www.ncbi.nlm.nih.gov/pubmed/35226211 http://dx.doi.org/10.1007/s10072-022-05918-y

Ejemplares similares

Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII)
por: Pasqualin, Francesca, et al.
Publicado: (2021)

Outcome measures and treatment effectiveness in late onset myasthenia gravis
por: Pasqualin, Francesca, et al.
Publicado: (2020)

Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

P-1 Prognostic factors and course of myasthenia gravis
por: Albertini, E., et al.
Publicado: (2011)

Impact of COVID-19 on a group of patients with myasthenia gravis
por: Sansone, Giulio, et al.
Publicado: (2021)

Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy
por: Iacomino, Nicola, et al.
Publicado: (2022)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011)

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
por: Mantegazza, Renato, et al.
Publicado: (2018)

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023)

Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports
por: Frangiamore, Rita, et al.
Publicado: (2021)

miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids
por: Bortone, Federica, et al.
Publicado: (2020)

Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study
por: Bonanno, Silvia, et al.
Publicado: (2018)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Immunoblot analysis of antiAChR antibodies in myasthenia gravis
por: Mantegazza, R., et al.
Publicado: (1988)

Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis
por: Cavalcante, Paola, et al.
Publicado: (2011)

Animal models of myasthenia gravis: utility and limitations
por: Mantegazza, Renato, et al.
Publicado: (2016)

Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale
por: Barnett, Carolina, et al.
Publicado: (2015)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Thymectomy for myasthenia gravis
por: Moorehead, R J, et al.
Publicado: (1985)

Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization
por: Iacomino, Nicola, et al.
Publicado: (2023)

Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

P-4 Evaluating therapy outcome in Mysthenia Gravis
por: Bisciglia, M., et al.
Publicado: (2011)

Thymectomy in Myasthenia Gravis
por: Dunlop, D. M.
Publicado: (1953)

Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?
por: Cavalcante, Paola, et al.
Publicado: (2017)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Thymectomy in Myasthenia Gravis
por: Brown, K. Paterson
Publicado: (1953)

Thymectomy for Myasthenia Gravis
por: Keynes, Geoffrey
Publicado: (1949)

The epidemiology of myasthenia gravis
por: Bubuioc, Ana-Maria, et al.
Publicado: (2021)

Diagnosis of Myasthenia Gravis
por: Rousseff, Rossen T.
Publicado: (2021)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Seronegative Maternal Ocular Myasthenia Gravis and Delayed Transient Neonatal Myasthenia Gravis
por: Townsel, Courtney, et al.
Publicado: (2016)

Development and validation of the Myasthenia Gravis Impairment Index
por: Barnett, Carolina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cve6ds8b7srm86adrtgvr3e1lt